Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients

Por Stonecipher, Karl G, Chia, Jenny, Onyenwenyi, Ahunna, Villanueva, Linda, Hollander, David A
Publicado em 2013

Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs

Por Xu, Keping, McDermott, Mark, Villanueva, Linda, Schiffman, Rhett M, Hollander, David A
Publicado em 2011

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model

Por Ackerman, Stacey, D’Ambrosio, Francis, Greiner, Jack V, Villanueva, Linda, Ciolino, Joseph B, Hollander, David A
Publicado em 2013

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye

Por Stonecipher, Karl G, Torkildsen, Gail L, Ousler, George W, Morris, Scot, Villanueva, Linda, Hollander, David A
Publicado no Clin Ophthalmol (2016)

Ocular Penetration and Anti-inflammatory Activity of Ketorolac 0.45% and Bromfenac 0.09% Against Lipopolysaccharide-Induced Inflammation

Por Waterbury, L. David, Galindo, Danielle, Villanueva, Linda, Nguyen, Cathy, Patel, Milan, Borbridge, Lisa, Attar, Mayssa, Schiffman, Rhett M., Hollander, David A.
Publicado em 2011

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials

Por McLaurin, Eugene B., Marsico, Nicholas P., Ackerman, Stacey L., Ciolino, Joseph B., Williams, Julia M., Villanueva, Linda, Hollander, David A.
Publicado em 2014

Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials

Por Ciolino, Joseph B, McLaurin, Eugene B, Marsico, Nicholas P, Ackerman, Stacey L, Williams, Julia M, Villanueva, Linda, Hollander, David A
Publicado no Clin Ophthalmol (2015)